In addition to controlling glycolipid metabolism and decreasing the buildup of inflammation and reactive oxygen species (ROS), a combination of a VEGF-B monoclonal antibody and interleukin-22 (IL-22) may protect against diabetic neuropathy [37]. This evidence concerns the gene IL22 and diabetic neuropathy.